Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery

CAR T-cell therapy is a cancer treatment that uses a patient’s own immune system cells, called T cells, after these cells have been modified to better recognize and kill the patient’s cancer. The T cells are engineered in the laboratory and then expanded to large numbers and infused back into the patient. This type of treatment transfers an immune system into the patient that is capable of immediately killing the cancer. CAR stands for chimeric antigen receptor, which represents the genetically engineered portion of the T cell. The CAR part of the T cell contains proteins that allow the T cells to recognize the specific cancer cells as well as become highly activated to kill the cancer cells.
Based on the Chimeric Antigen Receptor (CAR) T-Cell Therapy market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.

In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.

Key players in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market covered in Chapter 5:
Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.)
Celyad SA
Celgene Corp.
F. Hoffman La Roche AG
Transgene SA
Juno Therapeutics Inc. (A Celgene Company)
Shire Pharmaceuticals Inc.
Eureka Therapeutics Inc.
Cellectis
Formula Pharmaceuticals Inc.
Avacta Life Sciences Ltd.
Gilead Sciences
iCell Gene Therapeutics
Bellicum Phamaceuticals
Amgen
Servier Laboratories
Noile-Immune Biotech
Puretech Health
Editas Medicine Inc.
Medimmune Llc/Astrazeneca
Bluebird Bio
Mustang Bio Inc.
Novartis AG
Protheragen Inc.
Takeda Pharmaceuticals

In Chapter 6, on the basis of types, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market from 2015 to 2025 is primarily split into:
Acute Lymphoblastic Leukemia (ALL)
Advanced Lymphomas
Others

In Chapter 7, on the basis of applications, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market from 2015 to 2025 covers:
Children
Adult

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
United States
Canada
Mexico
Europe (Covered in Chapter 10)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 11)
China
Japan
South Korea
Australia
India
South America (Covered in Chapter 12)
Brazil
Argentina
Columbia
Middle East and Africa (Covered in Chapter 13)
UAE
Egypt
South Africa

Years considered for this report:

Historical Years:

2015-2019

Base Year:

2019

Estimated Year:

2020

Forecast Period:

2020-2025

Frequently Asked Questions